Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
The disruptions were also sex-specific — affecting donor liver cells of males and females in different...
A measure that would allow Texas residents to sue out-of-state abortion pill providers advanced to the...
Throughout the last two years, Gaza has faced widespread destruction as a result of Israel’s ongoing...
The U.S. is seeing a late summer surge in COVID-19 cases, tracking from the Centers for...
